Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621284 | 0.85 | CHRM3 (0.49) | CHRM3CHRM2CHRM1LMNAALDH1A1 | |
| SCHEMBL5243856 | 0.80 | CHRM3 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3622658 | 0.80 | CHRM3 (0.70) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3618917 | 0.78 | ALDH1A1 (0.40) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL3620063 | 0.77 | CNR1 (0.39) | CHRM3CHRM2CHRM1CNR1CNR2 | |
| SCHEMBL3618915 | 0.77 | CNR1 (0.42) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL13545706 | 0.72 | USP30 (0.38) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL4636570 | 0.69 | GAA (0.54) | LMNAALDH1A1KMT2A | |
| SCHEMBL3608442 | 0.69 | MEN1 (0.43) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL366365 | 0.68 | MAPT (0.58) | CNR1CNR2LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | claimed |
| EP-1828174-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | claimed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | claimed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
| EP-1828174-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006054162-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.